147 related articles for article (PubMed ID: 24729466)
21. Soluble receptor for advanced glycation end products alleviates nephritis in (NZB/NZW)F1 mice.
Lee SW; Park KH; Park S; Kim JH; Hong SY; Lee SK; Choi D; Park YB
Arthritis Rheum; 2013 Jul; 65(7):1902-12. PubMed ID: 23553192
[TBL] [Abstract][Full Text] [Related]
22. Induction of cross-reactive anti-dsDNA antibodies in preautoimmune NZB/NZW mice by immunization with bacterial DNA.
Gilkeson GS; Pippen AM; Pisetsky DS
J Clin Invest; 1995 Mar; 95(3):1398-402. PubMed ID: 7883986
[TBL] [Abstract][Full Text] [Related]
23. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus.
Bahjat FR; Pine PR; Reitsma A; Cassafer G; Baluom M; Grillo S; Chang B; Zhao FF; Payan DG; Grossbard EB; Daikh DI
Arthritis Rheum; 2008 May; 58(5):1433-44. PubMed ID: 18438845
[TBL] [Abstract][Full Text] [Related]
24. Contribution of major histocompatibility complex (MHC) to upregulation of anti-DNA antibody in transgenic mice.
Song YW; Tsao BP; Hahn BH
J Autoimmun; 1993 Feb; 6(1):1-9. PubMed ID: 8457281
[TBL] [Abstract][Full Text] [Related]
25. Strong acceleration of murine lupus by injection of the SmD1(83-119) peptide.
Riemekasten G; Kawald A; Weiss C; Meine A; Marell J; Klein R; Hocher B; Meisel C; Hausdorf G; Manz R; Kamradt T; Burmester GR; Hiepe F
Arthritis Rheum; 2001 Oct; 44(10):2435-45. PubMed ID: 11665986
[TBL] [Abstract][Full Text] [Related]
26. Anti-DNA antibody induction of protein kinase C phosphorylation and fibronectin synthesis in human and murine lupus and the effect of mycophenolic acid.
Yung S; Zhang Q; Zhang CZ; Chan KW; Lui SL; Chan TM
Arthritis Rheum; 2009 Jul; 60(7):2071-82. PubMed ID: 19565476
[TBL] [Abstract][Full Text] [Related]
27. EZH2 Inhibition Interferes With the Activation of Type I Interferon Signaling Pathway and Ameliorates Lupus Nephritis in NZB/NZW F1 Mice.
Wu L; Jiang X; Qi C; Zhang C; Qu B; Shen N
Front Immunol; 2021; 12():653989. PubMed ID: 33868295
[TBL] [Abstract][Full Text] [Related]
28. Suppression of renal disease and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus (SLE) by chenodeoxycholic acid.
Suwannaroj S; Lagoo A; McMurray RW
Lupus; 2001; 10(8):562-7. PubMed ID: 11530998
[TBL] [Abstract][Full Text] [Related]
29. Modulation of renal disease in autoimmune NZB/NZW mice by immunization with bacterial DNA.
Gilkeson GS; Ruiz P; Pippen AM; Alexander AL; Lefkowith JB; Pisetsky DS
J Exp Med; 1996 Apr; 183(4):1389-97. PubMed ID: 8666897
[TBL] [Abstract][Full Text] [Related]
30. Treatment of lupus nephritis in adult (NZB + NZW)F1 mice by cortisone-facilitated tolerance to nucleic acid antigens.
Borel Y; Lewis RM; André-Schwartz J; Stollar BD; Diener E
J Clin Invest; 1978 Feb; 61(2):276-86. PubMed ID: 304453
[TBL] [Abstract][Full Text] [Related]
31. Tuftsin-phosphorylcholine (TPC) equally effective to methylprednisolone in ameliorating lupus nephritis in a mice model.
Shemer A; Kivity S; Shovman O; Bashi T; Perry O; Watad A; Ben-Ami Shor D; Volkov A; Barshack I; Bragazzi NL; Krule A; Fridkin M; Amital H; Blank M; Shoenfeld Y
Clin Exp Immunol; 2018 Aug; 193(2):160-166. PubMed ID: 29698559
[TBL] [Abstract][Full Text] [Related]
32. Reversal of ongoing proteinuria in autoimmune mice by treatment with C-reactive protein.
Rodriguez W; Mold C; Kataranovski M; Hutt J; Marnell LL; Du Clos TW
Arthritis Rheum; 2005 Feb; 52(2):642-50. PubMed ID: 15692982
[TBL] [Abstract][Full Text] [Related]
33. Differences in expression of lupus nephritis in New Zealand mixed H-2z homozygous inbred strains of mice derived from New Zealand black and New Zealand white mice. Origins and initial characterization.
Rudofsky UH; Evans BD; Balaban SL; Mottironi VD; Gabrielsen AE
Lab Invest; 1993 Apr; 68(4):419-26. PubMed ID: 8479150
[TBL] [Abstract][Full Text] [Related]
34. Circulating levels of chromatin fragments are inversely correlated with anti-dsDNA antibody levels in human and murine systemic lupus erythematosus.
Jørgensen MH; Rekvig OP; Jacobsen RS; Jacobsen S; Fenton KA
Immunol Lett; 2011 Aug; 138(2):179-86. PubMed ID: 21530588
[TBL] [Abstract][Full Text] [Related]
35. Interferon-α accelerates murine systemic lupus erythematosus in a T cell-dependent manner.
Liu Z; Bethunaickan R; Huang W; Lodhi U; Solano I; Madaio MP; Davidson A
Arthritis Rheum; 2011 Jan; 63(1):219-29. PubMed ID: 20954185
[TBL] [Abstract][Full Text] [Related]
36. The beneficial effects of treatment with all-trans-retinoic acid plus corticosteroid on autoimmune nephritis in NZB/WF mice.
Nozaki Y; Yamagata T; Yoo BS; Sugiyama M; Ikoma S; Kinoshita K; Funauchi M; Kanamaru A
Clin Exp Immunol; 2005 Jan; 139(1):74-83. PubMed ID: 15606616
[TBL] [Abstract][Full Text] [Related]
37. Animal models utilized in the research of autoimmune disease control: experimental therapy of glomerulonephritis in NZB/W F1 mice.
Okudaira H; Terada E; Okudaira K
Prog Clin Biol Res; 1987; 229():157-74. PubMed ID: 3601985
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-21 receptor blockade inhibits secondary humoral responses and halts the progression of preestablished disease in the (NZB × NZW)F1 systemic lupus erythematosus model.
Zhang M; Yu G; Chan B; Pearson JT; Rathanaswami P; Delaney J; Ching Lim A; Babcook J; Hsu H; Gavin MA
Arthritis Rheumatol; 2015 Oct; 67(10):2723-31. PubMed ID: 26097207
[TBL] [Abstract][Full Text] [Related]
39. Cross-reactivity of human lupus anti-DNA antibodies with alpha-actinin and nephritogenic potential.
Zhao Z; Weinstein E; Tuzova M; Davidson A; Mundel P; Marambio P; Putterman C
Arthritis Rheum; 2005 Feb; 52(2):522-30. PubMed ID: 15693007
[TBL] [Abstract][Full Text] [Related]
40. Soluble human CD83 ameliorates lupus in NZB/W F1 mice.
Starke C; Steinkasserer A; Voll RE; Zinser E
Immunobiology; 2013 Nov; 218(11):1411-5. PubMed ID: 23886695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
